Abstract OT1-1-07: A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2)
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS624-TPS624
◽
2021 ◽